Among the tTG inhibitors, peptidomimetic irreversible inhibitors have achieved significant strides, with one of their representatives, ZED1227, successfully completing Phase 2a clinical trials for celiac disease, thus demonstrating its safety and validating tTG as a viable drug target23,24. The gene discussed is TGM2; the disease is celiac disease.